EVG Evgen Pharma Plc

TIDMEVG

RNS Number : 7558S

Evolution Group PLC

24 November 2011

The Evolution Group Plc

TR-1: Notification of Major Interests in Shares

24 November 2011

The Evolution Group Plc (the "Company") announces that it received notification today from Centaurus Capital Limited and Mr Bernard Oppetit of an acquisition of instruments with similar economic effect to qualifying financial instruments (CFD's).

In accordance with the Disclosure and Transparency Rules, on 22 November 2011 Deutsche Bank Nominees had a direct holding of voting rights in the Company of 5,811,015 ordinary shares of 1p each of the Company ("Shares") representing 2.5% of the issued Shares of the Company.

In addition Deutsche Bank Nominees has a CFD holding of 6,595,724 voting rights in the Company representing a 2.83% Delta interest in the issued Shares of the Company.

This notification is in respect of an increase in total voting rights to 12,406,739 Shares representing 5.33% of the issued Shares of the Company

The Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held is as follows: The investments are held by Deutsche Bank Nominees on account of a number of investment funds managed by Centaurus Capital Limited Partnership. Centaurus Capital Limited is the general partner of Centaurus Capital Limited Partnership. Centaurus Capital Limited is 100% owned by Centaurus Global Holdings Limited and that is in turn 100% owned by Mr Bernard Oppetit.

Contact: Mr Paul Leary 020 7852 3830.

For more information please contact:

The Evolution Group Plc

   Tony Lee, Company Secretary                                                 Tel: 0207 071 4300 

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLBIBRTMBJTBFB

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024